SUTRO BIOPHARMA, INC. reports

Location: South San Francisco, CA
Fiscal year end: 31 December

SUTRO BIOPHARMA, INC. has filed 608 SEC EDGAR filings since 08 Nov 2006

Filter by type:
10-K
10-Q
8-K
SC13D
SC13G

SEC filing history

Showing 101-125 of 603 matching filings.

Per page

25

Current page

5

SCHEDULE 13G File 005-90656

SCHEDULE 13G filing

Filing date: 04 Apr 2025
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

10-K File 001-38662

10-K

Filing date: 13 Mar 2025
Reporting date: 31 Dec 2024
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

8-K File 001-38662

8-K

Filing date: 13 Mar 2025
Reporting date: 13 Mar 2025
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

4

4 filing

Filing date: 07 Mar 2025
Reporting date: 05 Mar 2025
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 07 Mar 2025
Reporting date: 05 Mar 2025
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 07 Mar 2025
Reporting date: 05 Mar 2025
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 06 Mar 2025
Reporting date: 04 Mar 2025
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 06 Mar 2025
Reporting date: 04 Mar 2025
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 06 Mar 2025
Reporting date: 04 Mar 2025
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 06 Mar 2025
Reporting date: 04 Mar 2025
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 04 Mar 2025
Reporting date: 01 Mar 2025
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 04 Mar 2025
Reporting date: 01 Mar 2025
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 04 Mar 2025
Reporting date: 01 Mar 2025
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 04 Mar 2025
Reporting date: 01 Mar 2025
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 04 Mar 2025
Reporting date: 01 Mar 2025
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 04 Mar 2025
Reporting date: 01 Mar 2025
SEC evidence: Open document Open filing
Next action: Verify source filing

4

4 filing

Filing date: 04 Mar 2025
Reporting date: 28 Feb 2025
SEC evidence: Open document Open filing
Next action: Verify source filing

S-8 File 333-285346

S-8

Filing date: 27 Feb 2025
Reporting date: Not listed
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

8-K File 001-38662

8-K

Filing date: 10 Dec 2024
Reporting date: 10 Dec 2024
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

4

4 filing

Filing date: 03 Dec 2024
Reporting date: 01 Dec 2024
SEC evidence: Open document Open filing
Next action: Verify source filing

SC 13G/A File 005-90656

SUTRO BIOPHARMA, INC.

Filing date: 14 Nov 2024
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

SC 13G/A File 005-90656

AMENDMENT NO. 2 TO SCHEDULE 13G

Filing date: 14 Nov 2024
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

10-Q File 001-38662

10-Q

Filing date: 13 Nov 2024
Reporting date: 30 Sep 2024
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

SC 13G/A File 005-90656

SC 13G/A

Filing date: 13 Nov 2024
Reporting date: Not listed
SEC evidence: Open document Open filing
Next action: Verify source filing

8-K File 001-38662

8-K

Filing date: 13 Nov 2024
Reporting date: 13 Nov 2024
SEC evidence: Open document Open filing Open XBRL
Next action: Verify source filing

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .